Key result
In computational models of prolonged QT conditions, the hERG activator MC-II-157c reduced arrhythmia triggers by inhibiting afterdepolarisations but increased the arrhythmia substrate by widening the vulnerable window.
Why the study?
Does the hERG activator MC-II-157c reduce arrhythmia triggers and substrates in in silico models of prolonged QT interval?
Does the hERG activator MC-II-157c reduce arrhythmia triggers and substrates in in silico models of prolonged QT interval?
The hERG activator MC-II-157c reduces arrhythmia triggers but can increase the arrhythmia substrate (vulnerable window), highlighting a complex, multi-dimensional modulation of arrhythmia vulnerability in prolonged QT conditions.
Answers are grounded in this paper and cite their sources.
Raises caution for hERG activators in long QT due to expanded substrate; leaves open net arrhythmic risk in computational models.
Background: Prolongation of the QT interval of the electrocardiogram, underlain by prolongation of the action potential duration (APD) at the cellular level, is linked to increased vulnerability to cardiac arrhythmia. Pharmacological management of arrhythmia associated with QT prolongation is typically achieved through attempting to restore APD to control ranges, reversing the enhanced vulnerability to Ca2+-dependent afterdepolarisations (arrhythmia triggers) and increased transmural dispersion of repolarisation (arrhythmia substrate) associated with APD prolongation. However, such pharmacological modulation has been demonstrated to have limited effectiveness. Understanding the integrative functional impact of pharmacological modulation requires simultaneous investigation of both the trigger and substrate. Methods: We implemented a multi-scale (cell and tissue) in silico approach using a model of the human ventricular action potential, integrated with a model of stochastic 3D spatiotemporal Ca2+ dynamics, and parameter modification to mimic prolonged QT conditions. We used these models to examine the efficacy of the hERG activator MC-II-157c in restoring APD to control ranges, examined its effects on arrhythmia triggers and substrates, and the interaction of these arrhythmia triggers and substrates. Results: QT prolongation conditions promoted the development of spontaneous release events underlying afterdepolarisations during rapid pacing. MC-II-157c applied to prolonged QT conditions shortened the APD, inhibited the development of afterdepolarisations and reduced the probability of afterdepolarisations manifesting as triggered activity in single cells. In tissue, QT prolongation resulted in an increased transmural dispersion of repolarisation, which manifested as an increased vulnerable window for uni-directional conduction block. In some cases, MC-II-157c further increased the vulnerable window through its effects on INa. The combination of stochastic release event modulation and transmural dispersion of repolarisation modulation by MC-II-157c resulted in an integrative behaviour wherein the arrhythmia trigger is reduced but the arrhythmia substrate is increased, leading to variable and non-linear overall vulnerability to arrhythmia. Conclusion: The relative balance of reduced trigger and increased substrate underlies a multi-dimensional role of MC-II-157c in modulation of cardiac arrhythmia vulnerability associated with prolonged QT interval.
No takes yet. Share an insight, caveat, or question.
Colman et al. (2017) studied QT Prolongation and Arrhythmia. MC-II-157c vs. Prolonged QT conditions without drug was evaluated on Probability of spontaneous release events and vulnerable window for unidirectional conduction block. In computational models of prolonged QT conditions, the hERG activator MC-II-157c reduced arrhythmia triggers by inhibiting afterdepolarisations but increased the arrhythmia substrate by widening the vulnerable window.
Synapse has enriched 10 related papers. Consider them for comparative context: